8-K
filed October 2, 2024, 7:59 PM ET
CIK 0001769804
M&A
confidence high
sentiment neutral
materiality 1.00
Augmedix, Inc.: M&A transaction — Commure completes acquisition of Augmedix for $2.35/share; stock delisted
Augmedix, Inc.
- Merger completed Oct 2, 2024; Augmedix stockholders receive $2.35 per share in cash.
- Total consideration payable to equityholders approximately $139 million, funded by equity and cash.
- Augmedix becomes wholly owned subsidiary of Commure; common stock delisted from Nasdaq.
- All outstanding warrants terminated for no consideration; loan agreement repaid in full.
- Entire board resigned; Tanay Tandon named CEO, Daniel Brian CFO/Secretary of surviving company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Faulkner resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jason Krikorian resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Brian was appointed as Chief Financial Officer, Treasurer and Secretary at Augmedix, Inc..
- Action
- appointed
- Role
- Chief Financial Officer, Treasurer and Secretary
Exact text from the filing
Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Margie L. Traylor resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ian Shakil resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roderick H. O’Reilly resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tanay Tandon was appointed as President and Chief Executive Officer at Augmedix, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Emmanuel Krakaris resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Laurie A. S. McGraw resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William J. Febbo resigned as Director at Augmedix, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
As a result of the Merger, at the Effective Time, Emmanuel Krakaris, Roderick H. O’Reilly, Laurie A. S. McGraw, Jason Krikorian, Margie L. Traylor, William J. Febbo, Ian Shakil and Robert Faulkner each resigned from the board of directors of the Company (and from all of the committees thereof).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Brian was appointed as sole director at Augmedix, Inc..
- Action
- appointed
- Role
- sole director
Exact text from the filing
At the Effective Time, and upon the completion of the Merger, Daniel Brian was appointed as sole director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Deepika Bodapati was appointed as Chief Operating Officer at Augmedix, Inc..
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
Effective at the completion of the Merger, Tanay Tandon became President and Chief Executive Officer, Daniel Brian became Chief Financial Officer, Treasurer and Secretary and Deepika Bodapati became Chief Operating Officer of the Company.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Augmedix, Inc. underwent a change of control involving Commure, Inc. for $2.35 in cash (closed 2024-10-02).
- Action
- change of control
- Counterparty
- Commure, Inc.
- Consideration
- $2.35 in cash
- Closing
- 2024-10-02
Exact text from the filing
Time”), each issued and outstanding share of Augmedix’s common stock, par value $0.0001 per share (“Common Stock”), was canceled and converted into the right to receive $2.35 in cash, without interest (the “Merger Consideration”) and subject to any applicable tax withholdings, subject to certain exceptions set forth in the Merger Agreement. Harrigan
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.